Mu‐Chun Li

National Health Research Institutes — Taiwan

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index562citations28works3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(3), Phagocytosis and Immune Regulation(3), Cancer Mechanisms and Therapy(3), Glioma Diagnosis and Treatment(2), Lung Cancer Treatments and Mutations(2)

Publications28 total

Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix
Journal of Medicinal Chemistry·2025· 1 citedOpen Access
KIF2C promotes paclitaxel resistance by depolymerizing polyglutamylated microtubules
Developmental Cell·2025· 6 citedOpen Access
Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening
Advanced Science·2025· 3 citedOpen Access
Aldehyde dehydrogenases as drug targets for cancer: SAR and structural biology aspects for inhibitor design
Bioorganic Chemistry·2024· 6 cited
Discovery of novel TANK-Binding Kinase 1 (TBK1) inhibitor against pancreatic ductal adenocarcinoma
International Journal of Biological Macromolecules·2024· 2 cited
Discovery of Dual MER/AXL Kinase Inhibitors as Bifunctional Small Molecules for Inhibiting Tumor Growth and Enhancing Tumor Immune Microenvironment
Journal of Medicinal Chemistry·2024· 8 citedOpen Access
Abstract 1809: Discovery of novel AXL and MER inhibitors as potential anticancer and immunomodulatory drugs
Cancer Research·2024
Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer
Journal of Medicinal Chemistry·2023· 15 citedOpen Access
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Journal of Biomedical Science·2022· 151 citedOpen Access
Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization
European Journal of Medicinal Chemistry·2021· 16 citedOpen Access
Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design
ACS Omega·2021· 10 citedOpen Access
<scp>Tumor‐agnostic</scp> inhibitors in oncology: A new phase for precision medicine
Journal of the Chinese Chemical Society·2020· 1 cited
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors
Bioorganic Chemistry·2020· 9 cited
Design of drug-like hepsin inhibitors against prostate cancer and kidney stones
Acta Pharmaceutica Sinica B·2019· 17 citedOpen Access
Research on the Effectiveness of Board Governance Structure-Evidence from the Tourism Listed Companies in China
DEStech Transactions on Economics Business and Management·2017
Uterine tumor with neuroectodermal differentiation of advanced stage managed successfully with multimodal strategy
European Journal of Obstetrics & Gynecology and Reproductive Biology·2012· 8 cited
Monotypic epithelioid angiomyolipoma of the liver with TFE3 expression
Pathology·2010· 12 cited
A 32‐YEAR‐OLD MAN WITH A FOURTH VENTRICULAR MASS
Brain Pathology·2009· 4 citedOpen Access
Application of MSCT scanning technique on the diagnosis of infant tracheal and bronchial nonmetal foreign body
Zhongguo xiandai yixue/Zhongguo xiandai yixue zazhi·2009
Analysis of recurrence-related factors for differentiated thyroid carcinoma
China Medical Engineering·2009
page 1 of 2Next →

Frequent Co-authors

Hsing‐Pang Hsieh(14), Teng‐Kuang Yeh(4), Mohane Selvaraj Coumar(4), Wen‐Hsing Lin(3), Ling Chang(3), Shiow‐Lin Pan(3), Yee‐Jee Jan(3), Wan-Ching Yen(3), Han‐Chung Wu(2), Chun‐Ying Wu(2), Peichen Wang(2), Pei‐Yi Chen(2), Ching-Ping Chen(2), Chun-Hsien Chiu(2), Chiung‐Tong Chen(2), Shu‐Yu Lin(2), Guanlin Huang(2), Chen-Ming Yang(2), Mei‐Chin Wen(2), William L. Ho(2)